Schrodinger expects ACV to increase 12 to 17% this year off of 198; Bunsen remains in beta and the company is seeing license growth. The hosted transition targets 75% hosted by 2028.
SDGR · Schrodinger, Inc. · Documents
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
Schrodinger raised full-year 2026 ACV guidance to $222 to $232 million and drug discovery revenue guidance to $75 to $85 million after 17% third-quarter ACV growth.
Schrodinger generated revenue of $64.5 million for the three months ended September 30, 2026, up 19% from $54.3 million, while net loss widened to $37.7 million from $32.8 million.
Schrödinger reported third-quarter ACV of $44.7 million, up 17%, and raised 2026 ACV guidance to $222 million to $232 million and drug discovery revenue guidance to $75 million to $85 million. It clarified that no SGR-1505 combination study had been initiated under its FDA-cleared protocol.